ARS Pharmaceuticals (SPRY) Income from Continuing Operations (2020 - 2026)
ARS Pharmaceuticals (SPRY) reported Income from Continuing Operations of 95931000.0 for Q1 2026, down 156.94% on a YoY basis from 168478282.89 in Q1 2025, and down 119.7% sequentially from 43665000.0 in Q4 2025.
ARS Pharmaceuticals (SPRY) Income from Continuing Operations (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals (SPRY) has 7 years of Income from Continuing Operations data on file, last reported at 95931000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 156.94% year-over-year to 95931000.0; the trailing twelve-month figure through Mar 2026 stood at 474846000.0 (down 123.05% YoY), and the FY2025 full-year result was 171298000.0, down 2241.76% from the prior year.
- Income from Continuing Operations declined to 95931000.0 in Q1 2026, from 43665000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 47262000.0 in Q4 2024 to a low of 39407246000.0 in Q1 2023.
- A 5-year average of 5524273823.53 and a median of 67407000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations slumped 339646.93% in 2023 and surged 571.87% in 2024, its largest moves.
- Tracing SPRY's Income from Continuing Operations over 5 years: stood at 15136000.0 in 2022, then jumped by 33.83% to 10016000.0 in 2023, then surged by 571.87% to 47262000.0 in 2024, then sank by 192.39% to 43665000.0 in 2025, then tumbled by 119.7% to 95931000.0 in 2026.
- Business Quant data shows SPRY's Income from Continuing Operations at 95931000.0 in Q1 2026, 43665000.0 in Q4 2025, and 112977000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | ARS Pharmaceuticals | 595.78 Mn | 394.81 Mn | - | -95.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -95.93 Mn |
| Dec 31, 2025 | -43.67 Mn |
| Sep 30, 2025 | -112.98 Mn |
| Jun 30, 2025 | -222.27 Mn |
| Mar 31, 2025 | -37.34 Mn |
| Dec 31, 2024 | 47.26 Mn |
| Sep 30, 2024 | -155.41 Mn |
| Jun 30, 2024 | -67.41 Mn |
| Mar 31, 2024 | -90.90 Mn |
| Dec 31, 2023 | -10.02 Mn |
| Sep 30, 2023 | -15.46 Bn |
| Jun 30, 2023 | -38.20 Bn |
| Mar 31, 2023 | -39.41 Bn |
| Dec 31, 2022 | -15.14 Mn |
| Sep 30, 2022 | -15.16 Mn |
| Jun 30, 2022 | -13.54 Mn |
| Mar 31, 2022 | -11.60 Mn |
| Dec 31, 2021 | 47.19 Mn |
| Sep 30, 2021 | -44.42 Mn |
| Jun 30, 2021 | -145.94 Mn |